Would you consider adjuvant chemotherapy for a patient with HR+/HER2- breast cancer, luminal type A on Mammaprint, after knowing that the patient had a poor response to neoadjuvant endocrine therapy?

I'm going to assume this is an older patient who is postmenopausal, as current guidelines from ASCO state that neoadjuvant endocrine therapy (NET) should not be offered to premenopausal women.

My first question is: which specimen was tested? There was a nice poster looking at gene changes and Mammapr...